Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 18/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3598524 | 0.98 | REN (0.41) | RENSSTR4ALDH1A1LMNA | |
| SCHEMBL30149615 | 0.80 | SLC6A2 (0.45) | RENSSTR4 | |
| SCHEMBL2918828 | 0.80 | SLC6A2 (0.45) | RENSSTR4 | |
| Hydrochloric Acid SCHEMBL15010249 | 0.79 | SLC6A2 (0.46) | RENSSTR4 | |
| Hydrochloric Acid SCHEMBL23886824 | 0.79 | REN (0.37) | RENSSTR4 | |
| SCHEMBL22926241 | 0.77 | ALDH1A1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL295081 | 0.77 | SSTR4 (0.44) | RENSSTR4 | |
| SCHEMBL23230712 | 0.77 | SSTR4 (0.44) | RENSSTR4 | |
| SCHEMBL29018289 | 0.76 | SSTR4 (0.41) | RENSSTR4 | |
| SCHEMBL16471469 | 0.75 | REN (0.46) | RENSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | REN 79/4885SSTR4 1227/4885ALDH1A1 1550/4885 |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | REN 1207/4885SSTR4 3136/4885ALDH1A1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.